Effect of Direct-to-Consumer Genomewide Profiling to Assess Disease Risk

- New England Journal of Medicine
Author/s: -Bloss, Cinnamon S -Schork, Nicholas J -Topol, Eric J
Journal: New England Journal of Medicine
Year: 2011
Volume: 364
Pages: 524
Start Page: 524

The use of direct-to-consumer genomewide profiling to assess disease risk is controversial, and little is known about the effect of this technology on consumers. We examined the psychological, behavioral, and clinical effects of risk scanning with the Navigenics Health Compass, a commercially available test of uncertain clinical validity and utility.

URL: http://www.nejm.org/doi/full/10.1056/NEJMoa1011893